Safety of olmesartan in a patient with telmisartan-induced myotoxicity: a case report

Br J Clin Pharmacol. 2015 Jun;79(6):1034-6. doi: 10.1111/bcp.12569.

Authors

Manish J Barvaliya¹, Viren N Naik¹, Ashok C Shah², Chandrabhanu R Tripathi¹

Affiliations

¹ Department of Pharmacology, Government Medical College, Bhavnagar, Gujarat, India.
² Department of Medicine, Mangaltirth Nursing Home, Ahmedabad, Gujarat, India.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Angiotensin II Type 1 Receptor Blockers / adverse effects*
Antihypertensive Agents / adverse effects*
Benzimidazoles / adverse effects*
Benzoates / adverse effects*
Blood Pressure / drug effects
Drug Substitution*
Drug Therapy, Combination
Humans
Hypertension / diagnosis
Hypertension / drug therapy*
Hypertension / physiopathology
Imidazoles / therapeutic use*
Male
Middle Aged
Myalgia / chemically induced*
Myalgia / diagnosis
Telmisartan
Tetrazoles / therapeutic use*
Treatment Outcome

Substances

Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Benzimidazoles
Benzoates
Imidazoles
Tetrazoles
olmesartan
Telmisartan